We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP
Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations. He has worked in various B2B and B2C environments, including in leadership roles at Roland Berger, KaDeWe Group, Camp David, Grundig, and Thomas Cook. Most recently, he joins us from QE-3 Equity Partners.
At ROTOP, Dr. Peterseim will be responsible for Finance/Controlling, HR, and IT/Technology and will support the next phase of our growth, with a particular focus on process optimization and new construction investments.
Ähnliche Beiträge
Saxon State Parliament member Thomas Schmidt visits ROTOP
August 7, 2026 - A reunion with a long-standing companion: Saxon State Parliament member Thomas Schmidt visited our Radiopharmacy to learn about its development since its inauguration in 2020. The discussions focused on the future of radiopharmacy and nuclear medicine as well as the European framework for innovative diagnostic and therapeutic approaches.
ROTOP Receives Building Permit for New Radiopharmaceutical Manufacturing Facility in Dresden
April 27, 2026 - ROTOP Pharmaka GmbH today announced that it has received the building permit for a new radiopharmaceutical manufacturing facility in Dresden. The approval represents a major step in the company’s growth strategy and further strengthens its position as a leading radiopharmaceutical partner in Europe.
New CFO at ROTOP – Dr. Michael Peterseim
March 13, 2026 - We’re pleased to Welcome Dr. Michael Peterseim as our new Chief Financial Officer (CFO) at ROTOP. Dr. Peterseim brings many years of experience in financial leadership and has successfully guided companies through transformation processes, strengthened performance, and executed strategic transactions, particularly in growth situations.
